Protagonist Therapeutics, Inc. (PTGX)
154.70
+0.38
(+0.25%)
USD |
NASDAQ |
Aug 24, 16:00
154.70
0.00 (0.00%)
After-Hours: 20:00
Protagonist Therapeutics Shareholders Equity (Quarterly) : 841.54M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 841.54M |
| March 31, 2026 | 655.47M |
| December 31, 2025 | 614.71M |
| September 30, 2025 | 645.44M |
| June 30, 2025 | 668.02M |
| March 31, 2025 | 689.05M |
| December 31, 2024 | 675.30M |
| September 30, 2024 | 531.92M |
| June 30, 2024 | 541.32M |
| March 31, 2024 | 560.44M |
| December 31, 2023 | 336.68M |
| September 30, 2023 | 302.15M |
| June 30, 2023 | 294.07M |
| March 31, 2023 | 216.17M |
| December 31, 2022 | 215.61M |
| September 30, 2022 | 243.62M |
| June 30, 2022 | 267.98M |
| March 31, 2022 | 301.78M |
| December 31, 2021 | 300.02M |
| September 30, 2021 | 329.66M |
| June 30, 2021 | 357.45M |
| Date | Value |
|---|---|
| March 31, 2021 | 259.33M |
| December 31, 2020 | 279.61M |
| September 30, 2020 | 169.59M |
| June 30, 2020 | 167.48M |
| March 31, 2020 | 62.67M |
| December 31, 2019 | 79.96M |
| September 30, 2019 | 95.36M |
| June 30, 2019 | 84.32M |
| March 31, 2019 | 100.82M |
| December 31, 2018 | 112.52M |
| September 30, 2018 | 123.96M |
| June 30, 2018 | 107.66M |
| March 31, 2018 | 114.62M |
| December 31, 2017 | 120.63M |
| September 30, 2017 | 57.84M |
| June 30, 2017 | 61.03M |
| March 31, 2017 | 74.89M |
| December 31, 2016 | 87.56M |
| September 30, 2016 | 97.49M |
| June 30, 2016 | 20.41M |
| March 31, 2016 | 26.38M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Gilead Sciences, Inc. | 11.83B |
| Insmed, Inc. | 757.49M |
| Madrigal Pharmaceuticals, Inc. | 523.72M |
| AbbVie, Inc. | -5.935B |
| PTC Therapeutics, Inc. | -165.36M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 885.54M |
| Total Liabilities (Quarterly) | 44.00M |
| Debt to Equity Ratio | 0.011 |
| Current Ratio | 21.71 |
| Net Debt Paydown Yield | 0.01% |